McKesson reported fiscal second quarter 2027 consolidated revenues of $111.0 billion, an 8% increase year-over-year that surpassed analyst estimates. Adjusted earnings per diluted share reached $11.68, significantly beating expectations and prompting management to raise its full-year outlook. The results were bolstered by robust growth in specialty distribution and provider solutions within the Oncology & Multispecialty segment.
Key Highlights
- Adjusted EPS of $11.68 increased 18% year-over-year, beating the $10.69 estimate by $0.99.
- Oncology & Multispecialty segment revenue surged 24% to $15.0 billion, driven by strength in provider solutions.
- Management raised fiscal 2027 Adjusted EPS guidance to a range of $45.60 to $46.40, up from the previous midpoint of $44.60.
- The company returned $3.6 billion to shareholders in the first half of the fiscal year, including $3.4 billion in stock repurchases.
- Strategic extension of the pharmaceutical distribution partnership with CVS Health through June 2032.